Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY

Benzinga Newsdesk www.benzinga.com Negative 78.4%

Neg 78.4% Neu 0% Pos 0%

Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly losses of $(27.59) per share. This is a 24.45 percent increase over losses of $(36.52) per share from the same period last year. The company reported $0.00 in sales this quarter. This is the same as the same period last year.